National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tirbanibulin (Klisyri®). HTA ID: 21054

Tirbanibulin is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 15/11/2021
Rapid review completed 30/11/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that tirbanibulin not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.